Straits Times Index
3,265.60 +40.43 (+1.25%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,793.55 +281.86 (+1.71%) FTSE 100
8,023.87 0.00 (0.00%) Bitcoin USD
66,424.41 +112.77 (+0.17%) CMC Crypto 200
1,397.86 -16.90 (-1.19%)
Wave Life Sciences Ltd. (WVE)
After hours:
| Previous close | 4.8700 |
| Open | 4.9200 |
| Bid | 4.8200 x 200 |
| Ask | 4.8600 x 200 |
| Day's range | 4.6400 - 4.9400 |
| 52-week range | 3.1500 - 7.6700 |
| Volume | |
| Avg. volume | 903,429 |
| Market cap | 591.855M |
| Beta (5Y monthly) | -1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April. Cantor Virtual Muscular Dystrophy Symposium Date: Wednesday, April 3, 2024Analyst-led fireside chat presentation time: 3:10 p.m.
- GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry’s first-ever RNA editing candidate in the clinic; GalNAc pharmacology translating as expected and proof-of-mechanism data from patients wit
- GlobeNewswire
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the inve
